Gupta, Aditi
Budhu, Sadna http://orcid.org/0000-0002-3284-1408
Fitzgerald, Kelly
Giese, Rachel
Michel, Adam O.
Holland, Aliya
Campesato, Luis Felipe
van Snick, Jacques
Uyttenhove, Catherine
Ritter, Gerd http://orcid.org/0000-0002-3513-4661
Wolchok, Jedd D. http://orcid.org/0000-0001-6718-2222
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Article History
Received: 5 May 2020
Accepted: 4 October 2021
First Online: 17 November 2021
Competing interests
: J.D.W. is a paid consultant for Adaptive Biotech, Amgen, Apricity, Ascentage Pharma, Astellas, AstraZeneca, Bayer, Beigene, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Elucida, F Star, Imvaq, Janssen, Kyowa Hakko Kirin, Linneaus, Merck, Neon Therapeutics; Novartis, Polynoma, Psioxus, Recepta, Takara Bio, Trieza, Truvax, Serametrix, Surface Oncology, Syndax, Syntalogic. J.D.W. receives research support from Bristol Myers Squibb, AstraZeneca, Sephora. J.D.W. has stock option ownership in Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus. T.M. is a paid consultant for Immunos Therapeutics, Pfizer Co-founder and Equity in IMVAQ therapeutics. T.M. receives research support from Bristol Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Inc., Peregrine Pharmeceuticals, Inc., Adaptive Biotechnologies, Leap Therapeutics, Inc., Aprea. T.M. is an inventor on patent applications related to work on Oncolytic Viral therapy, Alpha Virus Based Vaccine, Neo Antigen Modeling, CD40, GITR, OX40, PD-1, and CTLA-4. The remaining author declares no competing interests.